Patents by Inventor Abdolamir Landi
Abdolamir Landi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240058438Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: ApplicationFiled: January 19, 2023Publication date: February 22, 2024Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Publication number: 20230310590Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.Type: ApplicationFiled: January 19, 2023Publication date: October 5, 2023Inventors: Michael Houghton, John L. Law, Michael Logan, Darren Hockman, Abdolamir Landi
-
Patent number: 11719694Abstract: The present disclosure provides methods and compositions that find use in identifying presence of an advanced stage autoimmune liver disease (ALD) is a subject diagnosed as having ALD. Also provided here are methods and compositions that find use in monitoring effectiveness of treatment of an ALD patient receiving a treatment for the ALD. Also provided here are methods and compositions that find use in identifying subjects suffering from a relapse of ALD. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject having ALD.Type: GrantFiled: October 10, 2018Date of Patent: August 8, 2023Assignee: The Governors of the University of AlbertaInventors: Abdolamir Landi, Michael Houghton, D. Lorne Tyrrell, Ferrucio Bonino, Maurizia Rossana Brunetto, Aldo Montano-Loza, Ana Clementin
-
Patent number: 11576967Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.Type: GrantFiled: December 15, 2020Date of Patent: February 14, 2023Assignee: The Governors of the University of AlbertaInventors: Michael Houghton, John L. Law, Michael Logan, Darren Hockman, Abdolamir Landi
-
Patent number: 11576968Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: GrantFiled: December 15, 2020Date of Patent: February 14, 2023Assignee: The Governors of the University of AlbertaInventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Publication number: 20220196674Abstract: The present disclosure provides methods and compositions that find use in identifying presence of an advanced stage autoimmune liver disease (ALD) is a subject diagnosed as having ALD. Also provided here are methods and compositions that find use in monitoring effectiveness of treatment of an ALD patient receiving a treatment for the ALD. Also provided here are methods and compositions that find use in identifying subjects suffering from a relapse of ALD. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject having ALD. Also provided herein are methods for treating ALD.Type: ApplicationFiled: April 17, 2019Publication date: June 23, 2022Inventors: Abdolamir LANDI, Michael HOUGHTON, D. Lorne J. TYRRELL, Ferrucio BONINO, Maurizia Rossana BRUNETTO, Aldo MONTANO-LOZA, Ana CLEMENTIN
-
Patent number: 11324818Abstract: The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.Type: GrantFiled: September 21, 2017Date of Patent: May 10, 2022Assignee: The Governors of the University of AlbertaInventors: Michael Houghton, Abdolamir Landi, Michael Logan, John L. Law, Darren Hockman, Chao Chen
-
Publication number: 20220105175Abstract: The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.Type: ApplicationFiled: October 26, 2021Publication date: April 7, 2022Inventors: Michael Houghton, Abdolamir Landi, Michael Logan, John L. Law, Darren Hockman, Chao Chen
-
Publication number: 20210170018Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: ApplicationFiled: December 15, 2020Publication date: June 10, 2021Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Publication number: 20210100895Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.Type: ApplicationFiled: December 15, 2020Publication date: April 8, 2021Inventors: Michael Houghton, John L. Law, Michael Logan, Darren Hockman, Abdolamir Landi
-
Publication number: 20210052721Abstract: The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.Type: ApplicationFiled: March 14, 2019Publication date: February 25, 2021Applicant: The Governors of the University of AlbertaInventors: Michael HOUGHTON, Abdolamir LANDI, Michael LOGAN, John L. LAW, Chao CHEN, Darren HOCKMAN
-
Patent number: 10881726Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: GrantFiled: October 5, 2017Date of Patent: January 5, 2021Assignees: The Governors of the University of Alberta, Helmholtz Center for Infection ResearchInventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Patent number: 10881727Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.Type: GrantFiled: April 3, 2019Date of Patent: January 5, 2021Assignee: The Governors of the University of AlbertaInventors: Michael Houghton, John L. Law, Michael Logan, Darren Hockman, Abdolamir Landi
-
Publication number: 20200217844Abstract: The present disclosure provides methods and compositions that find use in identifying presence of an advanced stage autoimmune liver disease (ALD) is a subject diagnosed as having ALD. Also provided here are methods and compositions that find use in monitoring effectiveness of treatment of an ALD patient receiving a treatment for the ALD. Also provided here are methods and compositions that find use in identifying subjects suffering from a relapse of ALD. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject having ALD.Type: ApplicationFiled: October 10, 2018Publication date: July 9, 2020Inventors: Abdolamir LANDI, Michael HOUGHTON, D. Lorne TYRRELL, Ferrucio BONINO, Maurizia Rossana BRUNETTO, Aldo MONTANO-LOZA, Ana CLEMENTIN
-
Patent number: 10641780Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.Type: GrantFiled: March 15, 2018Date of Patent: May 5, 2020Assignees: The Governors of the University of Alberta, Medizinische Hochschule HannoverInventors: Abdolamir Landi, Michael Houghton, D. Lorne Tyrrell, Tim Lankisch, Tobias Weismueller, Michael Manns
-
Patent number: 10408844Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a subject. The methods and compositions involve measurement of at least one of proteins: IL-16, IL-7, VEGF, CXCL9, CX3CL1, CCL24, CCL19, and CCL11 in a body fluid sample of a subject suspected of having CFS/ME. Levels of one or more of the aforementioned proteins can be used to facilitate a diagnosis of a CFS/ME and/or confirm a diagnosis of CFS/ME. The methods and compositions of the present disclosure also find use in screening subjects for clinical trials and facilitating treatment decisions for a subject.Type: GrantFiled: January 26, 2016Date of Patent: September 10, 2019Assignee: The Governors of the University of AlbertaInventors: Abdolamir Landi, David Broadhurst, D. Lorne J. Tyrrell, Michael Houghton
-
Publication number: 20190231867Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: ApplicationFiled: October 5, 2017Publication date: August 1, 2019Inventors: Michael Houghton, Abdolamir Landi
-
Publication number: 20190224308Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.Type: ApplicationFiled: April 3, 2019Publication date: July 25, 2019Inventors: Michael Houghton, John L. Law, Michael Logan, Darren Hockman, Abdolamir Landi
-
Publication number: 20190209677Abstract: The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.Type: ApplicationFiled: September 21, 2017Publication date: July 11, 2019Inventors: Michael Houghton, Abdolamir Landi, Michael Logan, John L. Law, Darren Hockman, Chao Chen
-
Patent number: 10300131Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.Type: GrantFiled: July 6, 2016Date of Patent: May 28, 2019Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTAInventors: Michael Houghton, John L. Law, Michael Logan, Darren Hockman, Abdolamir Landi